Sientra Seeks to Expand War Chest With Secondary Offering

Health and Healthcare

Published: September 4, 2015 11:35 am

Sientra Inc. (NASDAQ: SIEN) filed an S-1 form with the Securities and Exchange Commission (SEC) a secondary offering. No terms were given in the filing, but the offering is valued up to $86.25 million. The underwriters for the offering are Piper Jaffray, Stifel, Leerink Partners and William Blair.

On November 3, 2014, the company completed an initial public offering (IPO), whereby it sold a total of 5.75 million shares of common stock at $15.00 per share, inclusive of 750,000 shares sold to underwriters pursuant to the exercise in full of their option to purchase additional shares. The company received net proceeds from the IPO of roughly $77.0 million.

This medical aesthetics company is committed to making a difference in patients’ lives by enhancing their body image, growing their self-esteem and restoring their confidence. It was founded to provide greater choice to board-certified plastic surgeons and patients in need of medical aesthetics products. It has developed a broad portfolio of products with technologically differentiated characteristics, supported by independent laboratory testing and strong clinical trial outcomes.

Sientra sells its breast implants and breast tissue expanders, or Breast Products, exclusively to board-certified and board-admissible plastic surgeons and tailor customer service offerings to their specific needs. These advantages have allowed it to increase its market share each year since it entered the market in 2012.

The company detailed its finances as:

We commenced sales of our breast implants in the United States in the second quarter of 2012. Our net sales were $44.7 million, $35.2 million and $10.4 million for the years ended December 31, 2014, 2013 and 2012, respectively. Our net sales were $26.6 million and $21.9 million for the six months ended June 30, 2015 and 2014, respectively. Our net loss was $5.8 million, $19.1 million and $23.4 million for the years ended December 31, 2014, 2013 and 2012, respectively. Our net loss was $6.4 million and $1.2 million for the six months ended June 30, 2015 and 2014, respectively.

Shares of Sientra were down 0.9% at $22.95 on Friday. The stock has a consensus analyst price target of $28.33 and a post-IPO trading range of $12.53 to $26.67.

ALSO READ: 5 Analyst Stocks With Huge Upside Calls This Week

Smart Investors Are Quietly Loading Up on These “Dividend Legends”

If you want your portfolio to pay you cash like clockwork, it’s time to stop blindly following conventional wisdom like relying on Dividend Aristocrats. There’s a better option, and we want to show you. We’re offering a brand-new report on 2 stocks we believe offer the rare combination of a high dividend yield and significant stock appreciation upside. If you’re tired of feeling one step behind in this market, this free report is a must-read for you.

Click here to download your FREE copy of “2 Dividend Legends to Hold Forever” and start improving your portfolio today.